Search

Displaying results 2641 - 2650 of 5925 in total
  1. Drug

    Bromopride

    go.drugbank.com/drugs/DB09018
    Investigational

    Bromopride is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.

    Categories: Dopamine D2 Receptor Antagonists
  2. Drug

    Nadecnemab

    go.drugbank.com/drugs/DB16677
    Investigational

    Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee).

  3. Drug

    Veliflapon

    go.drugbank.com/drugs/DB16346
    Investigational

    Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).

  4. Drug

    24-Homo-1,25-dihydroxyvitamin D3

    go.drugbank.com/drugs/DB15557
    Experimental

    24-Homo-1,25-dihydroxyvitamin D3 is a novel [vitamin D] analogue.

    Synonyms: 24-Homo-1,25-dihydroxyvitamin D3Categories: Vitamin D and Analogues
  5. Drug

    QR-1123

    go.drugbank.com/drugs/DB17869
    Investigational

    QR-1123 is a first-in-class investigational RNA-based oligonucleotide designed to treat autosomal dominant retinitis pigmentosa due to the P23H mutation in the rhodopsin (_RHO_) gene.[L46782]

  6. Drug

    DR-01

    go.drugbank.com/drugs/DB18258
    Investigational

    DR-01 is a monoclonal antibody directed against human CD94.

  7. Drug

    Linseed oil

    go.drugbank.com/drugs/DB11357
    Investigational

    Linseed oil is particularly susceptible to polymerization reactions upon exposure to oxygen in air due to a high content of di- and triunsaturated esters.

  8. Drug

    Alosetron

    go.drugbank.com/drugs/DB00969
    ApprovedWithdrawn

    Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  9. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    [L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907]

  10. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    Gonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates